On January 12, 2023, Taysha Gene Therapies, Inc. and Suyash Prasad, the Company's Chief Medical Officer, mutually agreed to Dr. Prasad's separation from the Company, effective immediately. In connection with Dr. Prasad's separation from the Company, the Company intends to enter into a separation agreement with Dr. Prasad that will provide for the terms of Dr. Prasad's separation from employment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.95 USD | +2.33% | +15.16% | +123.16% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+123.16% | 722M | |
+51.85% | 59.28B | |
+41.42% | 40.94B | |
-5.25% | 40.17B | |
-5.16% | 28.69B | |
+12.79% | 26.63B | |
-20.18% | 18.89B | |
+30.88% | 12.46B | |
+0.61% | 12.42B | |
+25.06% | 12.26B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer